“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

However, his GP did not inform him about the drug's potential side effects, which include impulse control disorders such as ...

Methods: A retrospective drug utilization evaluation was conducted in patients who received levodopa or dopamine agonist for RLS from July 1, 2006, to July 31, 2007. Patients' medical records were ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...